Cancer Vaccine Week articles from March 2009

Cancer Vaccine Week archives from March 2009

New cancer vaccines findings from A. Wallecha and co-researchers published.
March 2, 2009... According to a study from the United States, "Listeria monocytogenes has been exploited previously as a vaccine vector for the delivery of heterologous proteins such as tumor-specific antigens for active cancer immunotherapy. However, for...

New cancer vaccines study findings have been published by scientists at University of North Carolina.(Report)
March 2, 2009... According to recent research published in the Journal of Immunology, "With a 5-year survival rate of "In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and...

New cancer vaccines study findings have been reported by E. Neninger and co-researchers.(Clinical report)
March 2, 2009... "An epidermal growth factor (EGF) vaccine was given before and after standard first line chemotherapy to patients with advanced nonsmall cell lung cancer (NSCLC), to investigate the immunologic and clinical results in a phase I Study. Twenty...

Antigenics Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights.(Financial report)
March 2, 2009... Antigenics Inc. (NASDAQ: AGEN) reported results today for the three months and year ended December 31, 2008. For the three months ended December 31, 2008, the company reported net income attributable to common stockholders of $5.1 million, or...

With over 120 Cancer Vaccines - Examine the Latest Drug Pipeline Updates in 2009.
March 2, 2009... Research and Markets (http://www.researchandmarkets.com/research/80cc74/cancer_vaccines_d) has announced the addition of the "Cancer Vaccines: Drug Pipeline Update 2009" report to their offering (see also Research and Markets). Cancer...

Findings from Erasmus University provide new insights into cancer vaccines.
March 9, 2009... "A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response," investigators in Netherlands report (see also Cancer Vaccines). "In...

New findings from University of California in the area of cancer vaccines described.
March 9, 2009... According to a study from the United States, "Tumor-specific variable regions of the clonal immunoglobulin (idiotype, Id) expressed by B cell non-Hodgkin lymphoma (NHL) can be targeted by active immunotherapy. We conducted a phase I/II trial to...

New findings in cancer vaccines described by S. Inoges and co-researchers.
March 9, 2009... "During the last 2 decades, idiotypic vaccination has provided proof of principle of biological efficacy, clinical efficacy and clinical benefit in small follicular lymphoma trials. However, with the exception of anecdotal reports, most...

Research from B. Duval and colleagues provide new insights into cancer vaccines.
March 9, 2009... According to recent research from Canada, "Cervical cancer prevention by vaccination: nurses' knowledge, attitudes and intentions. This paper is a report of a survey: (1) to document nurses' knowledge, attitudes and information needs regarding...

Research from University of Cologne reveals new findings on cancer vaccines.
March 9, 2009... "Cellular adjuvants such as dendritic cells (DC) are in the focus of tumour immunotherapy. In DC-vaccine trials, induction of tumour antigen-specific immunity is observed frequently and well-documented clinical responses have been reported,"...

Scientists at University of Zurich target cancer vaccines.(Report)
March 9, 2009... "The development of effective anti-cancer vaccines requires precise assessment of vaccine-induced immunity. This is often hampered by low ex vivo frequencies of antigen-specific T cells and limited defined epitopes," researchers in Zurich,...

Studies conducted at J. Ruter et al on cancer vaccines recently published.
March 9, 2009... "Cancers express tumor associated antigens that should elicit immune attack, but spontaneous immune rejection of established cancer is rare. Recent data demonstrate that specific and active tumor-mediated mechanisms hinder host anti-tumor...

Study data from University of Navarra update understanding of cancer vaccines.(Clinical report)
March 9, 2009... According to recent research from Spain, "During the last three decades, idiotypic vaccination has cleared all the hurdles between preclinical studies and randomized clinical trials, assuming the forerunner role among human therapeutic cancer...

Study findings from Y. Morera et al broaden understanding of cancer vaccines.
March 9, 2009... According to recent research from Havana, Cuba, "Following the clinical success of Bevacizumab, a humanized monoclonal antibody that affects the interaction between vascular endothelial growth factor (VEGF) and its receptors, blocking...

Research on glioblastoma detailed by W.Q. Yu and co-authors.
March 9, 2009... "Despite advances in surgical technology and radiation therapy, the prognosis in the patients with malignant glioma remains poor. Recent studies show that interleukin-13 receptor {alpha}2 chain (IL-13Ra2), a brain tumor-associated receptor for...

Research from Shandong University, Medical Department in the area of hepatitis B virus published.
March 9, 2009... "Hepatitis B virus (HBV) causes chronic hepatitis in hundreds of millions of people worldwide, which can eventually lead to hepatocellular carcinoma (HCC). The molecular mechanisms underlying HBV persistence are not well understood," scientists...

Research from Medical University of Vienna in the area of human papillomavirus described.(Report)
March 9, 2009... According to recent research published in the Journal of General Virology, "Evidence of a possible association of cutaneous human papillomavirus (HPV) types, especially members of the genus Betapapillomavirus, and the development of...

Study results from Vrije University, Medical Department broaden understanding of life sciences.
March 9, 2009... According to recent research published in the Journal of Immunology, "A20 is a zinc finger protein with ubiquitin-modifying activity. A20 has been described as negatively regulating signaling induced by the TNF receptor and TLR family in a...

Researchers from King Faisal Specialist Hospital and Research Center discuss findings in cancer vaccines immunology.
March 9, 2009... New investigation results, 'Enhancement of lytic activity of leukemic cells by CD8+ cytotoxic T lymphocytes generated against a WT1 peptide analogue,' are detailed in a study published in Leukemia & Lymphoma. "The Wilms tumor antigen 1 (WT1)...

National Institute of Biomedical Innovation publishes research in hepatitis C virus.(Report)
March 9, 2009... Research findings, 'Non-human primate surrogate model of hepatitis C virus infection,' are discussed in a new report. According to a study from Tsukuba, Japan, "More than 170 million people worldwide are chronically infected by HCV, which is...

Bavarian Nordic Reports Further Data on PROSTVAC(TM).
March 9, 2009... Bavarian Nordic announced that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available. The data, that once again confirms the excellent safety and efficacy results...

Bavarian Nordic Updates on Phase I/II Studies With Breast Cancer Vaccine.
March 9, 2009... Bavarian Nordic today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2. The study met its primary...

BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine.
March 9, 2009... BN ImmunoTherapeutics, Inc. today provided updated data from its clinical studies with its breast cancer vaccine, MVA-BN(R)-HER2, in development as therapy of metastatic breast cancer patients whose tumours over-express HER2. The study met its...

PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies.
March 9, 2009... PDS Biotechnology announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the...

Children's Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia.
March 9, 2009... Cincinnati Children's Hospital Medical Center has received a $6.7 million grant from the Bill & Melinda Gates Foundation to help prevent flu in pregnant women and their infants in rural areas around the world (see also Immunization). Most...

BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM).
March 9, 2009... BN ImmunoTherapeutics, Inc. announced that the first detailed data on PROSTVAC(TM) since the vaccine was licensed from the National Institutes of Health (NIH) is now available. The data, that once again confirms the excellent safety and...

"Immunotherapy in Oncology: Drug Pipeline Update 2009" Lists All Drugs and Gives You a Progress Analysis on Each One of Them.
March 9, 2009... Research and Markets(http://www.researchandmarkets.com/research/315ded/immunotherapy_in_o) has announced the addition of the "Immunotherapy in Oncology: Drug Pipeline Update 2009" report to their offering (see also Research and Markets). ...

UAB researchers report breakthrough in HPV research.
March 9, 2009... UAB (University of Alabama at Birmingham) researchers have developed a new, inexpensive and efficient method for producing and studying a type of human papillomavirus (HPV) that causes cervical cancer. The process could speed understanding of...

New cancer vaccines study findings have been published by X.X. Song and colleagues.
March 16, 2009... "Despite advances in the development of human papillomavirus (HPV) prophylactic vaccines, little progress has been made in the field of therapeutic vaccines in recent years. In the present study, we found a significant accumulation of immature...

Reports from Hebrew University highlight recent research in cancer vaccines.
March 16, 2009... According to recent research published in the journal Obstetrics and Gynecology, "Current randomized clinical trials have shown that the quadrivalent human papillomavirus (HPV) vaccine can reduce the morbidity of precancerous lesions associated...

Data on cancer vaccines published by researchers at University of Virginia, Department of Surgery.(Report)
March 16, 2009... Data detailed in 'Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules' have been presented. In this recent report...

Researchers from University of Pittsburgh, Department of Pathology describe findings in cancer vaccines therapy.
March 16, 2009... Current study results from the report, 'Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells,' have been published. "Suppression of dendritic cells (DCs) is a crucial...

Researchers from National Institutes of Health publish findings in immunization.
March 16, 2009... Scientists discuss in 'Antigen-presenting cells containing multiple costimulatory molecules promote activation and expansion of human antigen-specific memory CD8+ T cells' new findings in immunization. According to recent research from the...

College of Medicine details research in melanoma vaccines.
March 16, 2009... A report, 'Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma,' is newly published data in Cancer Immunology, Immunotherapy. "Anti-tumor...

IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs.
March 16, 2009... IDRI (Infectious Disease Research Institute) announced that Dr. Karen Auditore-Hargreaves has joined IDRI as Senior Vice President (SVP) Scientific Affairs to assist the organization in the execution of its research and development programs....

Analytical Tool - Cancer Vaccines.
March 16, 2009... Research and Markets (http://www.researchandmarkets.com/research/e24524/analytical_tool) has announced the addition of the "Analytical Tool - Cancer Vaccines" report to their offering (see also Research and Markets). "Analytical Tool -...

Pharmexa and Affitech to Combine Operations to Create a New Antibody Therapeutics Company.
March 16, 2009... Pharmexa A/S and Affitech AS announced that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the...

Data on cancer vaccines described by A.M. Dohnal et al.
March 23, 2009... "Manufacturing procedures for cellular therapies are continuously improved with particular emphasis on product safety. We previously developed a dendritic cell (DC) cancer vaccine technology platform that uses clinical grade lipopolysaccharide...

Data on cancer vaccines detailed by researchers at Vrije University Amsterdam.
March 23, 2009... According to a study from Netherlands, "We evaluated the cost-effectiveness of HPV16/18 vaccination to[girls aged 12 years in The Netherlands in addition to cervical cancer screening. For this purpose, we developed a simulation model that...

New cancer vaccines research reported from Leiden University.
March 23, 2009... "The tumor-associated self-antigen p53 is commonly overexpressed in cancer, including colorectal cancer, and can serve as a target for immunotherapy. The safety and immunogenicity of a p53 synthetic long peptide (p53-SLP) vaccine were...

Reports from Kurume University, Medical Department advance knowledge in cancer vaccines.(Report)
March 23, 2009... "We previously reported the SART3 gene to be a tumor-rejection antigen gene encoding a peptide at positions 109-118 (SART3(109 118)) with the ability to induce HLA-A24-restricted cytotoxic T lymphocytes. In this study, we investigated both...

Research from L.M. Ebert and co-researchers provides new data on cancer vaccines.
March 23, 2009... According to recent research from Heidelberg, Australia, "The tumor antigen NY-ESO-1 is a promising cancer vaccine target. We describe here a novel HLA-B7-restricted NY-ESO-1 epitope, encompassing amino acids 60-72 (APRGPHGGAASGL), which is...

Scientists at University of California describe research in life sciences.
March 23, 2009... "Polymeric carriers designed to encapsulate protein antigens have great potential for improving the efficacy of vaccines and immunotherapeutics for diseases such as cancer. We recently developed a carrier system based on polyacrylamide hydrogel...

Researchers from University of Leeds, Leeds Institute of Molecular Medicine publish findings in cancer vaccines.
March 23, 2009... Scientists discuss in 'The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma' new findings in cancer. According to recent research from Leeds, the United Kingdom, "To report the results of a...

Researchers from Wuhan University report on findings in cancer vaccines.(Report)
March 23, 2009... Researchers detail in 'Prevalence of single and multiple human papillomavirus types in cervical cancer and precursor lesions in Hubei, China,' new data in cancer vaccines. "The objective of this study was to establish the prevalence and type...

New cancer vaccines therapy data have been reported by researchers at University of Texas, M.D. Anderson Cancer Center.
March 23, 2009... A report, 'Treatment of B-cell chronic lymphocytic leukemia with nonchemotherapeutic agents: experience with single-agent and combination therapy,' is newly published data in Leukemia. According to a study from the United States, "Recent...

Antigenics' Oncophage Cancer Vaccine Receives European Orphan Drug Designation for Brain Cancer.
March 23, 2009... Antigenics Inc. (NASDAQ: AGEN) announced that Oncophage[R] (vitespen) has been granted a positive recommendation for orphan drug designation for the treatment of glioma by the Committee for Orphan Medical Products (COMP) of the European...

CEL-SCI Announces Exclusive Licensing Agreement for Cancer Drug Multikine(R) for Republic of South Africa.
March 23, 2009... CEL-SCI Corporation (NYSE Alternext US: CVM) announced that it has entered into an exclusive licensing agreement with Byron Biopharma ("Byron") under which CEL-SCI has granted Byron an exclusive license to market and distribute the Company's...

Both Latino and non-Latino women likely to accept HPV vaccination for selves and children.(Survey)
March 23, 2009... Most women responding to a survey conducted at Massachusetts General Hospital (MGH) clinics indicated they would be willing to be vaccinated against the human papillomavirus (HPV) and to have their daughters and even sons vaccinated in order to...

New cancer vaccines study results reported from M. Fujita et al.
March 30, 2009... According to recent research from the United States, "In an attempt to develop effective vaccines against central nervous system (CNS) tumors, we evaluated the ability of vaccines with standard dendritic cells (DC) versus type I polarizing DCs...

Recent studies from Queen Mary Hospital add new data to cancer vaccines.(Survey)
March 30, 2009... According to a study from Hong Kong, People's Republic of China, "To explore Chinese women's perceptions of human papillomavirus (HPV) vaccination and their intention to be vaccinated. A cross-sectional community-based survey study." ...

Scientists at National Cancer Institute target cancer vaccines.
March 30, 2009... "Human papillomavirus (HPV) virus-like particle (VLP) vaccines were recently licensed. Although neutralizing Ab titers are thought to be the main effectors of protection against infection, early predictors of long-term efficacy are not yet...

New data from University of Munich illuminate research in vaccines.
March 30, 2009... "Cancer vaccines aim to induce antitumor CTL responses, which require cross-presentation of tumor Ag to CTLs by dendritic cells (DCs). Adjuvants that facilitate cross-presentation of vaccine Ag are therefore key for inducing antitumor...

Researchers from McMaster University detail findings in adenovirus.
March 30, 2009... A new study, 'High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome,' is now available. According to a study from Canada, "We have investigated the therapeutic potential of a...

Medical Tourism - Choosing a Mexican Cancer Clinic.
March 30, 2009... Every year, thousands of US citizens travel to Mexico for cancer treatment, because clinics there offer non-toxic therapies and the cost is much less expensive, says TMD Unlimited, a medical tourism corporation. When Tom Teeter was diagnosed...

The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan.(Industry overview)
March 30, 2009... Despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. The patent expiry of key biopharmaceuticals has opened up numerous lucrative market opportunities, while driving the...

NKT Therapeutics Closes Series a Venture Round Led by SV Life Sciences and MedImmune Ventures.
March 30, 2009... NKT Therapeutics, Inc., a privately held biotechnology company, announced that it has closed an $8M Series A venture financing co-led by SV Life Sciences (SVLS) and MedImmune Ventures. As part of the transaction, Michael Ross, Ph.D., Managing...